驯龙高手2

Chinese researchers identify target to develop depression drug using traditional ethnic medicine in Yunnan_我的网站

俄罗斯转盘

一 | 新华社北京4月23日电（记者彭韵佳、徐鹏航）国家医保局规财法规司副司长谢章澍23日在全国智慧医保大赛新闻发布会上介绍，目前全国医保码用户已超11.2亿人，已接入定点医药机构超80万家，累计结算超60亿笔。

Qingyangshen, or Root of Auricledleaf Swallowwort, a traditional ethnic medicinal plant long used in Southwest China's Yunnan Province. Photo: Scrrenshot from website
A Chinese research team has identified a new potential target to develop antidepressant drug from Qingyangshen, or Root of Auricledleaf Swallowwort, a traditional ethnic medicinal plant long used in Southwest China's Yunnan Province, according to Kunming University of Science and Technology, Science and Technology Daily reported Sunday.
The team, led by professors Xu Tianrui and Xiang Cheng from the university's School of Life Science and Technology, found that Qingyangshen glycosides, the plant's core active compound, can alleviate depression-related behaviors by simultaneously suppressing inflammation, reducing oxidative damage and stabilizing neurotransmitters in the brain.
The findings were published in the international journal Phytomedicine.
Depression has become a widespread mental health disorder globally, while existing clinical drugs fail to provide effective treatment for more than 30 percent of patients, according to the researchers. Previous studies have established a strong link between chronic inflammation and depression, but existing anti-inflammatory drugs have limited targeting capabilities, underscoring the need for new therapeutic targets and lead compounds.
Qingyangshen, a plant of the Cynanchum genus in the Apocynaceae family, has long been used as a traditional medicine by ethnic groups including the Naxi, Yi and Bai peoples in Yunnan, mainly for treating neurological conditions such as epilepsy and neurasthenia.
The researchers systematically examined the pharmacological effects of Qingyangshen extract and its core active compound, Qingyangshen glycosides. Tests using mouse, zebrafish and fruit fly models repeatedly showed that the compound significantly improved depression-related behaviors induced by inflammation, according to the report.
To identify the compound's target, the team developed a dual-discrimination model for four subtypes of prostaglandin E2 receptors and combined it with AI-powered machine learning. The researchers screened hundreds of G protein-coupled receptors and identified the prostaglandin E2 subtype 4 receptor as the direct target of Qingyangshen glycosides.
Multiple molecular experiments confirmed that the compound binds directly to the receptor and acts as an inhibitory ligand. Further experiments involving animals with the receptor knocked out in the hippocampus showed that the antidepressant effects of Qingyangshen glycosides disappeared completely when the receptor was absent, providing the first in-vivo evidence that the receptor is essential for the compound's therapeutic effects.
An illustration of the research. Photo: Screenshot from the website

An illustration of the research. Photo: Screenshot from the website
The study establishes the prostaglandin E2 subtype 4 receptor as a potential new target for antidepressant drug development and points to a new approach to treating depression through inflammatory pathways. It also identifies Qingyangshen glycosides as a potential lead compound for developing highly targeted anti-inflammatory antidepressants, creating a research chain from ethnic medicinal plants and active compounds to drug targets and new drug development.
Global Times
。　　目前，医保码可在预约挂号、签到就诊、诊疗检查、报告查询、药房取药等全流程使用，减少排队等待时间，提升看病买药体验。

二 | 　　聚焦群众就医和医保需求，国家医保服务平台（包含网厅和App）已开通医保码、跨省异地就医备案、医保信息查询、医保移动支付、地方特色服务专区等服务模块，为参保群众提供信息查询、业务办理、待遇申请等线上综合服务。

三 | 　　“国家医保服务平台实名用户达4.5亿人，上线32个地方专区，涵盖100余项服务功能。”谢章澍介绍，此外于2022年3月底全面建成的全国统一医保信息平台，已接入约40万家定点医疗机构和40万家定点零售药店，覆盖全国13.4亿参保人。　　谢章澍表示，为创新医保便民服务，国家医保局正在打造医保便民“三电子两支付”服务体系，包括医保码、医保电子票据、医保电子处方、医保移动支付、医保可信支付等，联通就医购药全流程，形成服务优化全闭环，推动服务体验全新升级。　　“我们还将探索推进离线结算、数字人民币等与医保服务相结合，推动医疗与医保服务之间有效衔接，打造更立体、更多元的医保便民服务生态，以优质服务提升群众医保获得感。”谢章澍说。